Medisys receives FDA approval for NiC1800 system:
This article was originally published in Clinica
Executive Summary
Medisys has received US pre-marketing approval for its NiC1800, an innovative system designed to instantly destroy hypodermic needles at the point of use. The approval has been received earlier than expected, allowing Medisys to proceed with distribution of the NiC1800 in the US.